Literature DB >> 16005573

Repetitive transcranial magnetic stimulation: a possible novel therapeutic approach to eating disorders.

Shih-Jen Tsai1.   

Abstract

The two most common eating disorders, anorexia nervosa and bulimia nervosa, are characterized by aberrant eating patterns and disturbances in body image. Treatment involves combining individual, behavioural, group, and family therapies, possibly with medications. Studies have found that medication, chiefly antidepressants, could be of help in bulimia nervosa but the evidence is weaker for use in anorexia nervosa. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique that briefly stimulates or depresses cortical areas within the brain. It has been used in the treatment of various psychiatric disorders, especially major depression, which is a condition that patients with eating disorders often experience as a significant comorbidity. Given that both disorders may share a common pathogenesis, this report proposes that rTMS may represent an alternative strategy for the treatment of eating disorders. Other evidence that supports this notion comes from animal studies that show that rTMS can change feeding behaviours and central neurotransmitters related to the regulation of eating behaviours. Further investigation into the dose, duration and type of rTMS stimulus is needed to verify the efficacy of this intervention in eating disorders.

Entities:  

Mesh:

Year:  2005        PMID: 16005573     DOI: 10.1016/j.mehy.2005.05.020

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

Review 1.  Potential role of repetitive transcranial magnetic stimulation in obesity.

Authors:  Rami Bou Khalil; Charline El Hachem
Journal:  Eat Weight Disord       Date:  2013-12-11       Impact factor: 4.652

2.  [Transcranial magnetic stimulation for comorbid depression in anorexia].

Authors:  S Kamolz; M M Richter; A Schmidtke; A J Fallgatter
Journal:  Nervenarzt       Date:  2008-09       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.